Literature DB >> 33205234

Integrated multi-omics profiling of nonfunctioning pituitary adenomas.

Zhenqing Wei1,2, Cuiqi Zhou3, Minghui Li4, Ruocheng Huang4, Hongjuan Deng5, Stephen Shen3, Renzhi Wang6.   

Abstract

PURPOSE: Genetic and epigenetic alterations are involved in pituitary adenoma pathogenesis, however the molecular basis of proliferative nonfunctioning pituitary adenomas (NFPAs) remains unclear. Here, we analyzed integrated multi-omics profiling including copy number variation (CNV), DNA methylation and gene expression of 8 NFPAs.
METHODS: We collected 4 highly proliferative (hpNFPA, Ki-67 ≥ 3) and 4 lowly proliferative (Ki-67 ≤ 1) NFPAs, and comprehensively assessed CNV, DNA methylation, and gene expression by Illumina HumanMethylation450 BeadChip and Affymetrix GeneChip PrimeView Human Gene Expression Array. We performed Ingenuity Pathway Analysis (IPA) for differentially expressed genes to illustrate aberrant pathways and delineated protein-protein networks of selected key genes in dysregulated pathways.
RESULTS: Aberrant arm level CNV, dysregulated DNA methylation, and associated impacts on gene expressions were observed in 2 early occurring hpNFPAs. Chromosomal losses were associated with attenuated expression of DNA methyltransferases, further altering global methylation in these 2 samples. Correlation analysis between DNA methylation and gene expression in 8 NFPAs indicates methylation in promoter and gene body regions are both involved in gene regulation. IPA showed PPARα/RXRα, dopamine receptor signaling, cAMP-mediated signaling, and calcium signaling were all activated, while p38 MAPK and ERK5 signaling were inhibited in hpNFPAs. Moreover, selected key gene networks in hpNFPAs exhibited concurrent methylation status and expression levels of adenylate cyclase genes, G protein subunits, HLA genes, CXCL12, and CCL2.
CONCLUSION: This study presents comprehensive multi-omics views of CNV, DNA methylation, and gene expression in 8 NFPAs. Pathway analysis and network maps of key genes provide clues to elucidate the molecular basis of hpNFPA.

Entities:  

Keywords:  Copy number variation; DNA methylation; Gene expression; Multi-omics profiling; Nonfunctioning pituitary adenoma

Mesh:

Substances:

Year:  2020        PMID: 33205234     DOI: 10.1007/s11102-020-01109-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  59 in total

1.  Pituitary adenoma predisposition caused by germline mutations in the AIP gene.

Authors:  Outi Vierimaa; Marianthi Georgitsi; Rainer Lehtonen; Pia Vahteristo; Antti Kokko; Anniina Raitila; Karoliina Tuppurainen; Tapani M L Ebeling; Pasi I Salmela; Ralf Paschke; Sadi Gündogdu; Ernesto De Menis; Markus J Mäkinen; Virpi Launonen; Auli Karhu; Lauri A Aaltonen
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

Review 2.  Pituitary-Tumor Endocrinopathies.

Authors:  Shlomo Melmed
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

Review 3.  Molecular genetics of multiple endocrine neoplasia types 1 and 2.

Authors:  Stephen J Marx
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 4.  The genetics of pituitary adenomas.

Authors:  Silvia Vandeva; Marie-Lise Jaffrain-Rea; Adrian F Daly; Maria Tichomirowa; Sabina Zacharieva; Albert Beckers
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

5.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

Review 6.  Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.

Authors:  Gerald Raverot; Emmanuel Jouanneau; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2014-03-13       Impact factor: 6.664

7.  Incidental pituitary macroadenoma: a population-based study.

Authors:  G M Nammour; J Ybarra; M H Naheedy; J H Romeo; D C Aron
Journal:  Am J Med Sci       Date:  1997-11       Impact factor: 2.378

Review 8.  Imaging of pituitary pathology.

Authors:  Michael Buchfelder; Sven Schlaffer
Journal:  Handb Clin Neurol       Date:  2014

9.  Refractory pituitary adenoma: a novel classification for pituitary tumors.

Authors:  Congxin Dai; Ming Feng; Xiaohai Liu; Sihai Ma; Bowen Sun; Xinjie Bao; Yong Yao; Kan Deng; Yu Wang; Bing Xing; Wei Lian; Dingrong Zhong; Wenbin Ma; Renzhi Wang
Journal:  Oncotarget       Date:  2016-12-13

10.  Pangenomic Classification of Pituitary Neuroendocrine Tumors.

Authors:  Mario Neou; Chiara Villa; Roberta Armignacco; Anne Jouinot; Marie-Laure Raffin-Sanson; Amandine Septier; Franck Letourneur; Ségolène Diry; Marc Diedisheim; Brigitte Izac; Cassandra Gaspar; Karine Perlemoine; Victoria Verjus; Michèle Bernier; Anne Boulin; Jean-François Emile; Xavier Bertagna; Florence Jaffrezic; Denis Laloe; Bertrand Baussart; Jérôme Bertherat; Stephan Gaillard; Guillaume Assié
Journal:  Cancer Cell       Date:  2019-12-26       Impact factor: 31.743

View more
  3 in total

Review 1.  Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.

Authors:  Busra Aydin; Aysegul Caliskan; Kazim Yalcin Arga
Journal:  EPMA J       Date:  2021-06-26       Impact factor: 8.836

2.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

Review 3.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.